THE SCIENCE
Our Approach
NextPoint is launching a new world of precision therapeutics that can combine direct tumor killing with immunomodulation through its leading scientific work on the novel B7-H7/HHLA2 axis. Our team of proven drug developers is advancing an antibody-drug-conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint inhibitor. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed modality, so that we can deliver first-in-class therapies to a broad range of cancer patients with B7-H7 upregulation including those who do not benefit from currently approved therapies such as PD-1/L1 inhibitors.
EXCITING NEW TARGET
Our Founders Independently Discovered a Novel B7 Receptor Checkpoint Axis
- Clinical opportunities independent of established immunotherapies
- Broad pipeline maximizing opportunities for immunomodulation and tumor-targeting through B7-H7
- All first-in-class assets with a strong IP position
STRATEGY
Targeting A Novel Immuno-Oncology Checkpoint and Tumor-Associated Antigen
Our Pipeline
Broad pipeline maximizing opportunities for immunomodulation and tumor-targeting by exploiting all aspects of the B7-H7 axis
|
Discovery
|
Ab Development
|
DC Selection
|
Manufacturing
|
GLPtox/IND
|
Clinical
|
|---|
|
Discovery
|
Clinical
|
|---|
ABOUT US
One pathway, many possibilities
First-in-class opportunity
NextPoint is launching a new world of immuno-oncology and tumor-targeting through its leading scientific work on the novel B7-H7/HHLA2 pathway.
Attractive Monotherapies
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients including those who do not benefit from PD-1/L1 inhibitors.
Precision oncology
OUR TEAM
World-class team
We are building a world-class team to help us realize the full potential of our scientific founders’ exciting discoveries and to shape the future of immuno-oncology and tumor-targeting
Ivan Cheung, MBA
Chief Executive Officer
Leena Gandhi, MD, PhD
Chief Medical Officer
Tatiana Novobrantseva, PhD
Chief Scientific Officer
Gordon Freeman, PhD
Dana-Farber Cancer Institute
XingXing Zang, PhD
Albert Einstein College of Medicine
QUOTES FROM
OUR FOUNDERS
The combined expertise and research of Gordon Freeman, PhD (Dana-Farber Cancer Institute) and XingXing Zang, PhD (Albert Einstein College of Medicine) form the basis of NextPoint Therapeutics. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology and tumor targeting.
I’m fascinated by the HHLA2 pathway because it looks like an alternative, non-redundant pathway than PD-L1 for turning off the anti-tumor immune response. I want Nextpoint to test whether it can be as effective as blocking PD-L1. Can we catch lightning twice?
- Gordon Freeman, PhD
From the discovery of the HHLA2 immune checkpoint pathway in 2013 to the first-in-class clinical trial targeting this pathway in 2023, NextPoint Therapeutics is revolutionizing the landscape of immuno-oncology and offering new hope for a broad spectrum of human cancer patients unresponsive to existing PD-1/L1 inhibitors.
- XingXing Zang, PhD
Investors & partners
We’re proud to collaborate with visionary investors and esteemed partners who share our commitment to advancing the field of precision immuno-oncology and tumor-targeting therapeutics
Careers
Join us at NextPoint Therapeutics and be part of a team pioneering immuno-oncology advancements
Clinical Development Leader
Check out the open positions on our LinkedIn
Send us an email with your resume
